Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 2, 2011, Pages 230-237

  Fridlender, Zvi G ^a,b   Kapoor, Veena ^a   Buchlis, George ^a   Cheng, Guanjun ^a   Sun, Jing ^a   Wang, Liang Chuan S ^a   Singhal, Sunil ^a   Snyder, Linda A ^c   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c CENTOCOR INC   (United States)

Author keywords

CCL2; Lung cancer; Mesothelioma; Tumor immunology; Tumor associated macrophages

Indexed keywords

MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL STRUCTURE; COMBINED IMMUNODEFICIENCY; FEMALE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOKINE CCL2; FEMALE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MACROPHAGES; MESOTHELIOMA; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MURINAE; MUS;

EID: 79551543576     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0080OC     Document Type: Article

References (49)

1. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006;12:4794-4803.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267.
3. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004;14:149-154.
4. Loberg RD, Ying C, Craig MJ, Yan L, Snyder L, Pienta KJ. CCL2 is an important mediator of prostate cancer growth in vivo via regulation of macrophage infiltration. Neoplasia 2007;9:556-562.
5. Jordan J, Sun W, Hussain S, DeAngulo G, Prabhu S, Heimberger A. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123-131.
6. Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res 1997;57:4849-4854.
7. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005;106:3322-3330.
8. Hu K, Xiong J, Ji K, Sun H, Wang J, Liu H. Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominanted cytokines and inhibits melanoma metastasis. Immunol Lett 2007;113:19-28.
9. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wonjo K, Snyder LA, Yan L, Pienta KJ. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007;67:9417-9424.
10. Cai Z, Chen Q, Chen J, Lu Y, Xiao G, Wu Z, Zhou Q, Zhang J. Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia 2009;11:228-236.
11. Arenberg D, Keane M, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Lannettoni MD, Strieter RM. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother 2000;49:63-70.
12. Nagai E, Ogawa T, Kielian T, Ikubo A, Suzuki T. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate preexisting tumors in syngeneic mice. Cancer Immunol Immunother 1998;47:72-80.
13. Nokihara H, Yanagawa H, Nishioka Y, Yano S, Mukaida N, Matsushima K, Sone S. Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res 2000;60:7002-7007.
14. Sarafi MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med 1997;185:99-110.
15. Tsui P, Das A, Whitaker B, Tornetta M, Stowell N, Kesavan P, Kaiser E, Lacy ER, Yan L, Snyder LA, Sweet R. Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies. Hum Antibodies 2007;16:117-125.
16. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu T. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-26.
17. Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, Suzuki E, Kinniry PA, Sterma DH, Kaiser LR, Albelda SM. Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 2005;65:8379-8387.
18. Fitzpatrick D, Bielefeldt-Ohman H, Himbeck R, Jarnicki A, Marzo A, Robinson B. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29-44.
19. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, vanHagen D, Robinson BWS, Nelson DJ. IL-2 intratumoral immunotherapy enhances CD81 T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003;171:5051-5063.
20. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LS, Heitjan DF, Snyder LA, Albelda SM. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010;70:109-118.
21. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, Albelda SM. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006;12:214-222.
22. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-6721.
23. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998;187:601-608.
24. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006;116:2132-2141.
25. Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang G, Osada S, Balazs M, Adany R, et al. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes. J Leukoc Biol 2008;84:679-688.
26. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, Jensen MC. Tumor-derived chemokine MCP-1/CCL2 Is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007;179:3332-3341.
27. + T cells. J Immunol 2008;180:2886-2893.
28. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001;166:6483-6490.
29. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009;69:1685-1692.
30. Allavena P, Sica A, Garlanda C, Mantovani A. The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008;222:155-161.
31. Loberg RD, Day LL, Harwood J, Ying C, St. John LN, Giles R, Neeley CK, Pienta KJ. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 2006;8:578-586.
32. Salcedo R, Ponce M, Young H, Wasserman K, Ward JM, Kleinman HK, OPPenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34-40.
33. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vingaud JM. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002;140:320-328.
34. + T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005;65:11752-11761.
35. Valkovic T, Fuckar D, Stifter S, Matusan K, Hasan M, Dobrila F, Jonjic N. Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma. J Cancer Res Clin Oncol 2005;131:453-458.
36. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555.
37. + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009;284:34342-34354.
38. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
39. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-3446.
40. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008;205:1261-1268.
41. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-4592.
42. Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang G, Feng Z. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007;252:86-92.
43. Man S, Munoz R, Kerbel R. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 2007;26:737-747.
44. Yamaura T, Doki Y, Murakami K, Saiki I. Model for mediastinal lymph node metastasis produced by orthotopic intrapulmonary implantation of lung cancer cells in mice. Hum Cell 1999;12:197-204.
45. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26:513-523.
46. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008;44:191-200.
47. van Golen KL, Ying C, Sequeira L, Dubyk CW, Reisenberger T, Chinnaiyan AM, Pienta KJ, Loberg RD. CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. J Cell Biochem 2008;104:1587-1597.
48. Kawai Y, Kaidoh M, Yokoyama Y, Sano K, Ohhashi T. Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. Cancer Sci 2009;100:419-428.
49. Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997;71:257-266.